A first-in-man clinical study with intraputamenal CDNF, a Phase I-II randomized, placebo-controlled, double-blind, multicenter clinical study in patients with advanced PD (>10 years since first motor symptoms) was conducted by Herantis Pharma Plc. Here, CDNF is linked to Parkinson disease.